Diplomat to sell Eli Lilly’s new cancer drug
October 10, 2017Diplomat Pharmacy will dispense newly approved Eli Lilly’s Verzenio(abemaciclib), a twice-daily oral therapy for advanced breast cancer.
Verzenio is indicated as a combination treatment with FASLODEX (fulvestrant) in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
VERZENIO is also approved as a monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
“This therapy represents yet another step forward in the way the health care community approaches treating advanced stages of this disease. We are proud to support patients dealing with breast cancer by dispensing Verzenio,” said Joel Saban, Diplomat president.
According to the American Cancer Society, breast cancer is the second most common cancer in American women, with more than 250,000 diagnoses expected in 2017.
